The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Moby Strategic Execution and Operational Pivot. Achieved a significant financial turning point in 2025 by reducing operating expenses ...

Amidst shifting regulatory landscapes, the federal agency issues a rare procedural rejection regarding a respiratory immunization candidate, sparking debate over clinical trial standards and future ...

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.